ANI Reports Q4 Revenue of $247.1M, Beating Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Should l Buy ANIP?
Reports Q4 revenue $247.1M, consensus $231.03M. "2025 was a year of significant growth for our Rare Disease and Generics businesses, which drove expansion to both our top- and bottom-line," said Nikhil Lalwani, President and CEO of ANI. "We are building on this momentum as we continue to focus on our key 2026 priority of accelerating our transformation into a leading Rare Disease company, supported by strong execution in Generics and disciplined capital deployment." Lalwani continued, "We see a significant multi-year growth opportunity for Cortrophin Gel as we expand in underpenetrated specialty indications and launch a dedicated organization for acute gouty arthritis flares. With a proven track record, we expect to deliver more than $1 billion in revenue in 2026, with Rare Disease representing approximately 60% of total revenue, while continuing to fulfill our purpose of Serving Patients, Improving Lives."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANIP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANIP
Wall Street analysts forecast ANIP stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 76.900
Low
100.00
Averages
115.00
High
124.00
Current: 76.900
Low
100.00
Averages
115.00
High
124.00
About ANIP
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ANI Pharmaceuticals Executive Sells Shares
- Insider Stock Sale: Thomas Rowland, an executive at ANI Pharmaceuticals, sold 4,772 shares in an open-market transaction on March 11, 2026, totaling $357,471, indicating a trend of insider selling within the company.
- Ownership Stake Change: Following this transaction, Rowland's direct ownership decreased by 11%, leaving him with 38,730 shares, which may reflect concerns about the company's future growth prospects.
- Transaction Price Analysis: The shares were sold at $74.91 each, approximately 3.8% above the market price of $72.17 as of March 17, 2026, suggesting that the executive capitalized on a favorable market condition.
- Company Financial Performance: ANI Pharmaceuticals reported record revenue of $883.4 million in 2025, a 43.8% year-over-year increase, highlighting strong growth in its rare disease segment, although insider selling may raise market concerns about the company's trajectory.
See More
Novartis Proposes Acquisition of Excellergy to Expand Immunology Pipeline
- Acquisition Scale: Novartis has announced a proposed acquisition of Excellergy for up to $2 billion, including upfront and milestone payments, expected to close in the second half of 2026, demonstrating the company's strategic commitment to expanding its immunology pipeline.
- Therapeutic Potential: Exl-111, a next-generation anti-IgE antibody currently in phase I trials, could significantly broaden Novartis' market reach across high-value indications such as food allergies and chronic urticaria if clinical data validate early findings.
- Enhanced Allergy Portfolio: This acquisition complements Novartis' existing allergy product line, particularly the co-promoted Xolair with Roche, further solidifying its deep expertise in IgE biology and supporting long-term growth in the immunology sector.
- Market Performance and Outlook: Novartis shares have risen 33% over the past year, significantly outperforming the industry growth of 10.1%, and despite facing generic competition for key drugs, the company is banking on key growth drivers like Kisqali and Kesimpta to support revenue growth.
See More
ANI Pharmaceuticals Reports Record Q4 2025 Earnings with Strategic Growth Plans
- Significant Revenue Growth: ANI Pharmaceuticals reported Q4 2025 revenues of $247.1 million, a 30% increase year-over-year, with full-year revenues reaching $883.4 million, highlighting the company's strong growth potential in rare diseases and generics.
- Cortrophin Gel Performance: Cortrophin Gel generated $111.4 million in Q4, up 76% year-over-year, with expectations to achieve $540 million to $575 million in 2026, underscoring its market leadership in treating acute gout flares.
- Strategic Team Expansion: The company established a dedicated 90-person team focused on marketing for acute gout flares, aiming to enhance awareness and adoption of Cortrophin, with a target of exceeding $1 billion in revenue and a 23% growth rate in 2026.
- Optimistic Future Outlook: ANI reaffirmed its 2026 revenue guidance of $1.055 billion to $1.115 billion, anticipating that rare disease products will account for 60% of total revenue, while emphasizing disciplined capital allocation to manage market risks.
See More
ANI Pharma (ANIP) Q4 2025 Earnings Call Transcript
See More
ANI Pharmaceuticals Reports Strong Q4 Earnings Growth
- Earnings Beat: ANI Pharmaceuticals reported adjusted earnings of $2.33 per share for Q4, a 43% increase from $1.63 a year ago, surpassing the consensus estimate of $2.00, indicating a significant improvement in profitability.
- Significant Revenue Growth: Total net revenues for Q4 reached $247.1 million, marking a 29.6% year-over-year increase and exceeding the consensus estimate of $231.53 million, reflecting strong performance in the rare disease segment.
- Rare Disease Segment Surge: The Rare Disease segment saw a remarkable 50.8% growth, contributing $131.3 million to overall revenue, indicating sustained demand for products like Cortrophin Gel and driving overall performance.
- Optimistic Future Outlook: The company expects to exceed $1 billion in sales for 2026, with the Rare Disease segment projected to represent 60% of total revenue, showcasing long-term growth potential and further solidifying its market position in this area.
See More
ANI Pharma Shares Climb Following Strong Quarterly Results Exceeding Expectations
Quarterly Results: Refile-Buzz-Ani Pharma reported quarterly results that exceeded market estimates.
Market Reaction: The positive earnings report has led to a favorable response from investors and analysts.
See More
ANI Pharmaceuticals Executive Sells Shares
- Insider Stock Sale: Thomas Rowland, an executive at ANI Pharmaceuticals, sold 4,772 shares in an open-market transaction on March 11, 2026, totaling $357,471, indicating a trend of insider selling within the company.
- Ownership Stake Change: Following this transaction, Rowland's direct ownership decreased by 11%, leaving him with 38,730 shares, which may reflect concerns about the company's future growth prospects.
- Transaction Price Analysis: The shares were sold at $74.91 each, approximately 3.8% above the market price of $72.17 as of March 17, 2026, suggesting that the executive capitalized on a favorable market condition.
- Company Financial Performance: ANI Pharmaceuticals reported record revenue of $883.4 million in 2025, a 43.8% year-over-year increase, highlighting strong growth in its rare disease segment, although insider selling may raise market concerns about the company's trajectory.
See More
Novartis Proposes Acquisition of Excellergy to Expand Immunology Pipeline
- Acquisition Scale: Novartis has announced a proposed acquisition of Excellergy for up to $2 billion, including upfront and milestone payments, expected to close in the second half of 2026, demonstrating the company's strategic commitment to expanding its immunology pipeline.
- Therapeutic Potential: Exl-111, a next-generation anti-IgE antibody currently in phase I trials, could significantly broaden Novartis' market reach across high-value indications such as food allergies and chronic urticaria if clinical data validate early findings.
- Enhanced Allergy Portfolio: This acquisition complements Novartis' existing allergy product line, particularly the co-promoted Xolair with Roche, further solidifying its deep expertise in IgE biology and supporting long-term growth in the immunology sector.
- Market Performance and Outlook: Novartis shares have risen 33% over the past year, significantly outperforming the industry growth of 10.1%, and despite facing generic competition for key drugs, the company is banking on key growth drivers like Kisqali and Kesimpta to support revenue growth.
See More
ANI Pharmaceuticals Reports Record Q4 2025 Earnings with Strategic Growth Plans
- Significant Revenue Growth: ANI Pharmaceuticals reported Q4 2025 revenues of $247.1 million, a 30% increase year-over-year, with full-year revenues reaching $883.4 million, highlighting the company's strong growth potential in rare diseases and generics.
- Cortrophin Gel Performance: Cortrophin Gel generated $111.4 million in Q4, up 76% year-over-year, with expectations to achieve $540 million to $575 million in 2026, underscoring its market leadership in treating acute gout flares.
- Strategic Team Expansion: The company established a dedicated 90-person team focused on marketing for acute gout flares, aiming to enhance awareness and adoption of Cortrophin, with a target of exceeding $1 billion in revenue and a 23% growth rate in 2026.
- Optimistic Future Outlook: ANI reaffirmed its 2026 revenue guidance of $1.055 billion to $1.115 billion, anticipating that rare disease products will account for 60% of total revenue, while emphasizing disciplined capital allocation to manage market risks.
See More
ANI Pharma (ANIP) Q4 2025 Earnings Call Transcript
See More
ANI Pharmaceuticals Reports Strong Q4 Earnings Growth
- Earnings Beat: ANI Pharmaceuticals reported adjusted earnings of $2.33 per share for Q4, a 43% increase from $1.63 a year ago, surpassing the consensus estimate of $2.00, indicating a significant improvement in profitability.
- Significant Revenue Growth: Total net revenues for Q4 reached $247.1 million, marking a 29.6% year-over-year increase and exceeding the consensus estimate of $231.53 million, reflecting strong performance in the rare disease segment.
- Rare Disease Segment Surge: The Rare Disease segment saw a remarkable 50.8% growth, contributing $131.3 million to overall revenue, indicating sustained demand for products like Cortrophin Gel and driving overall performance.
- Optimistic Future Outlook: The company expects to exceed $1 billion in sales for 2026, with the Rare Disease segment projected to represent 60% of total revenue, showcasing long-term growth potential and further solidifying its market position in this area.
See More
ANI Pharma Shares Climb Following Strong Quarterly Results Exceeding Expectations
Quarterly Results: Refile-Buzz-Ani Pharma reported quarterly results that exceeded market estimates.
Market Reaction: The positive earnings report has led to a favorable response from investors and analysts.
See More
